Nasdaq:TMDX
TransMedics Group, Inc.
A life-science pioneer using Normothermic Regional Perfusion technology to double organ viability and solve the global shortage of transplantable organs.
Key Metrics
Investment Thesis
Bull Case
TMDX represents a transformative play on solving the critical global organ shortage, with its NRP technology creating a new supply line for transplantable hearts and lungs. The financial trajectory is compelling, evidenced by a six-fold revenue expansion and a complete reversal to profitability with $190.3M in net income, backed by a healthy cash position of nearly half a billion dollars. Investors are buying into a monopoly-like potential in the organ care space where every additional transplant represents a significant value multiplier.
Bear Case
Despite strong recent gains, the stock carries high volatility risks typical of early-stage medical technology companies with limited operating history beyond 2023. Investors must weigh the substantial capital expenditures of $59.3M against the potential for regulatory hurdles that could cap the total addressable market for their proprietary machines. Additionally, the reliance on a single technology platform means any failure in clinical efficacy or supply chain disruption could severely impact the high revenue growth achieved in 2024 and 2025.
About TransMedics Group, Inc.
TransMedics Group, Inc. (TMDX) is a medical technology innovator specializing in Organ Care Systems that extend the viability of donor organs prior to transplantation. The company primarily serves hospitals and transplant centers globally, enabling the expansion of organ supply chains through its proprietary Normothermic Regional Perfusion (NRP) technology. With revenue surging from $93.5M in 2022 to $605.5M in 2025, TMDX has transitioned from a loss-making entity to a profitable growth leader in the organ transplant sector.
Analysis
Management Discussion
The company has executed a remarkable turnaround, driven by aggressive market adoption that pushed revenue up from $93.5M in 2022 to $605.5M in 2025, a six-fold increase. Operating leverage is now evident as net income swung from a loss of $36.2M in 2022 to a strong $190.3M profit in 2025, supported by high gross margins and improved working capital management. The shift from negative cash flow in investing activities of -$59.3M to positive operating cash flow of $192.8M demonstrates the business model's maturation and ability to self-fund growth.
Industry Overview
The organ transplant industry is facing a severe shortage where demand vastly outstrips supply, making technological solutions like TMDX's Normothermic Regional Perfusion highly valuable. Traditional cold storage limits organ viability to roughly four hours, whereas TMDX's technology extends this window significantly, unlocking a massive latent market of otherwise discarded organs. As global transplant lists grow annually, companies that can increase organ availability are poised to capture significant market share and pricing power.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $93.5M | $241.6M | $441.5M | $605.5M |
| Cost of Revenue | $28.2M | $87.5M | $179.5M | $242.7M |
| Gross Profit | $65.3M | $154.1M | $262.1M | $362.8M |
| Operating Expenses | $96.7M | $182.8M | $224.6M | $254.2M |
| Operating Income | $-31.4M | $-28.7M | $37.5M | $108.6M |
| R&D | $26.8M | $36.1M | $56.0M | $69.1M |
| G&A | $69.9M | $119.6M | $168.6M | $185.2M |
| Stock-Based Comp | $10.3M | $19.8M | $33.2M | $36.9M |
| D&A | $3.5M | $8.2M | $19.8M | $27.2M |
| Amortization | — | $100.0K | $200.0K | $200.0K |
| Other OpEx | $0 | $27.2M | $0 | $0 |
| Non-Operating Income | $-4.7M | $2.1M | $-1.7M | $-1.1M |
| Interest Expense | $3.7M | $10.8M | — | — |
| Pre-Tax Income | $-36.2M | $-26.7M | $35.8M | $107.5M |
| Income Tax | $66.0K | $-1.7M | $316.0K | $-82.8M |
| Continuing Ops | $-36.2M | $-25.0M | $35.5M | $190.3M |
| Discontinued Ops | $0 | $-57.0K | $0 | $0 |
| Net Income | $-36.2M | $-25.0M | $35.5M | $190.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-36.2M | $-25.0M | $35.5M | $190.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $252.3M | $510.7M | $497.2M | $637.8M |
| Cash & Equivalents | $201.2M | $394.8M | — | — |
| Accounts Receivable | $27.6M | $63.6M | $97.7M | $84.3M |
| Inventory | $20.6M | $44.2M | $46.6M | $48.9M |
| Prepaid Expenses | $2.9M | $8.0M | $16.3M | $16.3M |
| Other Current Assets | $0 | $0 | $336.6M | $488.4M |
| Long-Term Assets | $24.9M | $195.4M | $306.9M | $430.6M |
| PP&E (Net) | $19.2M | $173.9M | $286.0M | $327.7M |
| Intangibles | — | $2.4M | $2.2M | $1.9M |
| Goodwill | — | $12.0M | $11.5M | $11.5M |
| Operating Leases | $5.1M | $6.5M | $6.5M | $5.2M |
| Other LT Assets | $500.0K | $562.0K | $708.0K | $84.3M |
| Total Assets | $277.1M | $706.0M | $804.1M | $1.07B |
| Current Liabilities | $23.7M | $54.9M | $59.9M | $89.3M |
| Accounts Payable | $3.3M | $12.7M | $10.3M | $10.3M |
| Current Debt | — | — | — | $10.0M |
| Current Leases | $1.4M | $2.0M | $2.7M | $3.3M |
| Deferred Revenue | $241.0K | $2.0M | $1.7M | $2.9M |
| Other Current Liab | $18.6M | $38.2M | $45.2M | $62.7M |
| Long-Term Liabilities | $66.1M | $513.9M | $515.6M | $506.0M |
| Long-Term Debt | $58.7M | — | — | — |
| LT Operating Leases | $7.4M | $7.7M | $6.2M | $3.6M |
| Other LT Liab | $0 | $506.2M | $509.3M | $502.4M |
| Total Liabilities | $89.8M | $568.8M | $575.5M | $595.3M |
| Shareholders' Equity | $187.4M | $137.2M | $228.6M | $473.1M |
| Retained Earnings | $-478.7M | $-503.7M | $-468.2M | $-277.9M |
| AOCI | $-225.0K | $-199.0K | $-364.0K | $124.0K |
| Total L&E | $277.1M | $706.0M | $804.1M | $1.07B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-36.2M | $-25.0M | $35.5M | $190.3M |
| Non-Cash Adjustments | $-37.2M | $-71.8M | $-39.8M | $-10.9M |
| Working Capital Changes | $27.6M | $83.8M | $53.1M | $13.5M |
| Cash from Operations | $-45.8M | $-13.0M | $48.8M | $192.8M |
| Capital Expenditures | $11.9M | $151.8M | $129.7M | $59.3M |
| Cash from Investing | $54.5M | $-194.0M | $-129.3M | $-59.3M |
| Debt Issuances | $58.5M | — | — | — |
| Debt Repayments | $36.0M | — | — | — |
| Cash from Financing | $167.9M | $400.4M | $22.9M | $16.9M |
| FX Effect | $-1.0M | $193.0K | $-536.0K | $1.3M |
| Net Change in Cash | $175.6M | $193.6M | $-58.2M | $151.7M |
| Beginning Cash | $26.1M | $201.7M | $395.3M | $337.1M |
| Ending Cash | $201.7M | $395.3M | $337.1M | $488.9M |
Frequently Asked Questions
How does TransMedics Group, Inc. make money?
1) Organ Care Systems (Primary): Revenue derived from leasing and servicing NRP machines that keep donor hearts, lungs, and kidneys warm and functional during transport. 2) Service & Support: Recurring revenue streams from maintenance contracts, consumables sales, and remote monitoring services for hospital clients. 3) Clinical Trials & R&D: Income generated from research partnerships and data collection on expanded organ usage protocols.
What are the main risks for TMDX?
1) Regulatory Approval Timeline: Dependence on continued FDA clearance for new organ types or international market expansions could delay revenue growth if approval processes stall. 2) Clinical Trial Outcomes: Any negative data from ongoing studies regarding long-term transplant success rates could impact market trust and stock valuation. 3) Scalability of Manufacturing: Rapid demand growth may outpace the company's ability to manufacture and distribute NRP machines without significant capital expenditure increases.
What is TMDX's competitive advantage?
1) Proprietary NRP Technology: Exclusive control over a platform that successfully doubles the number of viable donor hearts available for transplantation compared to traditional cold storage methods. 2) High Switching Costs & Recurring Revenue: Once hospitals integrate TMDX systems into their transplant workflows, they rely on continuous support services and consumables, creating a stable cash flow base. 3) Strong Balance Sheet Conversion: The company recently achieved robust profitability with $190.3M net profit in 2025 and significant cash reserves of $488.9M, positioning it well against competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.